Association of knowledge on ART line of treatment, scarcity of treatment options and adherence

Habib O. Ramadhani¹,²*, Charles Muiruri⁴, Venance P. Maro¹, Michael Omondi⁶, Julian B. Mushí⁵, Eileen S. Lirhunde⁶ and John A. Bartlett³,⁴

Abstract

Background: Adherence to Antiretroviral Therapy (ART) is critical piece in the management of HIV infected patients. Despite the benefits of ART, non-adherence to ART persists. This study explores association between patient’s knowledge of the ART line of treatment, availability of future treatment options and adherence.

Methods: A cross sectional survey of HIV infected adolescent and adults was conducted. Cumulative optimal and sub-optimal adherence was defined as percentage adherence of ≥ 95 % and < 95 %, respectively. Binomial regression models were used to assess the association of patient’s knowledge of the ART line of treatment, availability of future treatment options and adherence.

Results: Of the 402 patients reviewed, 101 (25.1 %) patients knew their ART line of treatment and were aware that future treatment options are limited. Compared to those who were not aware of the ART line of treatment and/or scarcity of future treatment options, those who were aware were more likely to be adherent (adjusted prevalence ratio [APR], 1.1; 95 % CI, 1.0–1.3).

Conclusion: The study reports knowledge of patient’s ART line of treatment and future treatment options is important indicator of adherence to ART. Although majority of the patients did not have the knowledge, those who had the knowledge demonstrated to be more adherent. It is critical for the physicians/health care providers in these settings to clearly educate patients about ART line of treatment and limited availability of future treatment options as such information is likely to influence individual behavior and improve patient’s adherence to ART.

Keywords: HIV, Anti-retro-viral, Adherence, Knowledge of ART line of treatment

Background

Adherence to antiretroviral therapy (ART) is essential for the successful management of HIV-infected patients. Clinical trials and observational studies have repeatedly shown that patients taking their prescribed medications as recommended are likely to be virologically suppressed [1–3]. Despite the benefits of ART and the known need to adhere, non-adherence to ART persists. Recent findings indicate that patients who were non-adherent to first line ART continued to be non-adherent to second-line ART, suggesting that ART non-adherence is still a major concern in the management of HIV-infected patients [4]. Furthermore, in most resource-limited settings only two lines of ART are available. Advances in ART-based HIV treatment and preventive strategies such as “Treatment as Prevention” (TasP), including prevention of mother to child transmission (PMTCT) and pre-exposure prophylaxis (PreP), have shown promising results in preventing HIV transmission. For example, treatment of the HIV-infected member in sero-discordant couple reduced the risk of new HIV infections in the un-infected partner [5]; however, the success of such strategies requires high degree of medication adherence. To be virally suppressed, at least 95 % adherence is required for a number of combined ART regimens [6] and
for those containing boosted protease inhibitors, adherence of at least 80% is warranted [7, 8].

Barriers to adherence with ART have been explored [9–11]; however, the association between a patient’s knowledge of the ART line of treatment, awareness of the availability of future treatment options, and adherence to ART is lacking. Although non-adherence to ART medications may be primarily considered a personal behavioral problem, continued support with clear understanding of ART line of treatment as well as patient awareness of the limited availability of treatment options may be beneficial in improving patient ART adherence. For example, patient awareness of the limited availability of second-line ART following first-line ART failure may modify individual behavior and hence improve adherence. Due to the expenses associated with second-line ART as well as limited availability of future treatment options among patients failing first-line ART, we sought to explore the association between a patient’s knowledge of the ART line of treatment, the availability of future treatment options, and adherence. In most resource limited settings including Tanzania, second-line ART is the final salvage regimen following first line failure. It is not known if knowledge of ART line of treatment and awareness of the limited availability of future treatment options may be associated adherence to ART. Whether patients who have the knowledge of the ART line of treatment and are aware that future treatment options are limited are likely to be more adherent than those without this knowledge it is not understood. Exploring association between knowledge of limited treatment options and adherence is critical because such a finding will add to the existing body of knowledge of factors associated with adherence, and potential interventions that improve patient adherence with ART. We explored this association using both cross-sectional and longitudinally collected observational data from five care and treatment centers (CTC) located within Kilimanjaro Region in Northern Tanzania.

Methods
Study design and population
We used a cross-sectional study design to evaluate the association of knowledge of ART line of treatment, and the limited availability of future ART treatment options, with adherence to first-line ART. The study population included HIV-infected adolescent and adult patients attending CTCs at the Kilimanjaro Christian Medical Center (KCMC), Mawenzi Regional Hospital (MRH), Kibosho, and Kilema District Hospitals, and Majengo Health Center in Northern Tanzania between January 2004 and May 2015. These CTCs offer treatment according to the Tanzanian Ministry of Health treatment guidelines for the provision of ART. This is a secondary data analysis involving participants who are part of the primary study that explores predictors of viral suppression among HIV-infected patients in those clinics. Only participants who have been on treatment for at least 2 years in the primary data were included.

Data collection
After obtaining informed consent, standardized questionnaires translated into Kiswahili were administered to participating patients by trained research nurses. Among other things, questionnaire addressed demographic characteristics, knowledge of ART line of treatment, and availability of future treatment options.

As part of routine HIV clinical care in Tanzania, all patient data including demographics, medication use, adherence indicators (good adherence (G) = fewer than 2 missed days per month/poor adherence (P) = 2 or more missed days per month), were collected on standardized forms by health care providers in those clinics and entered into the National database. These standardized forms were reviewed for an adherence assessment, and all patients with adherence information for at least 24 months from the last clinic visit were included. Recognizing adherence wanes over time cumulative adherence rating was used [12, 13]. For this study, percentage adherence was then recalculated using 24 months of observations as the common denominator, adherence = [number of recorded G’s/(P + G)]*100. For example, a person with 22 recorded G’s and two recorded P’s has an adherence of 91.7%. The resulting adherence percentage was later dichotomized as optimal (adherence ≥ 95%) or sub-optimal (adherence < 95%) based on previous findings [6]. A near perfect adherence defined by adherence ≥ 95% is widely used for sustained viral suppression [14]. Cumulative adherence assessment has been used by other studies [4, 15].

Definition of variables
The primary endpoint was the cumulative percentage adherence to first-line ART, as defined above. The exposure of interest was the participant’s knowledge of ART line of treatment, and the availability of future treatment options. Patients were asked series of questions such as “which line of treatment are you on?”, “can you mention other line of treatment?” and “have you been told that apparently second-line is the final regimen at your clinic?” Using this information we defined knowledge on ART = 1 if participants correctly stated his/her ART line of treatment (first-line or second-line) and were aware that future treatment options were limited. Knowledge on ART was scored as zero if participants did not know their ART line of treatment and/or were not aware that future treatment options were limited. We verified the ART line of treatment reported by patients through a review of their medical records. Other variables were evaluated including age, gender, duration on first-line ART, treatment sites, marital
status, education, plasma HIV RNA levels (if available), and CD4 cell count at the time of interview.

Statistical analyses
Statistical analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC). Frequencies of categorical variables were calculated as the proportions of patients sampled. Crude and adjusted binomial regression models were used to assess the association of a patient’s knowledge of ART line of treatment, availability of future treatment options and adherence. All associations were presented as adjusted prevalence ratios (APRs) with 95% confidence intervals (CIs). Estimates whose CI crossed 1 were considered non-statistically significant. All other variables were added into the model and backward elimination was done with the final model having variables whose change in estimate was ≥ 10%.

Results
We surveyed a sample of 450 patients who were on ART between January 2004 and May 2014. Of these, 402 (89.3%) were on first-line ART and were used for final analysis. Most were female (271, 67%), and the majority were between 30 and 55 years old (301; 75%); (Table 1). The greatest proportion of patients came from Mawenzi Regional Hospital (223; 53%). Most patients were not aware that they were on first-line ART (321; 80%), and were unaware that future treatment options were limited (317; 79%). Approximately half of patients had been on first-line ART for longer than 5 years (199; 50%). The majority had less than primary school education (332; 83%), 199 (49.5%), and 183 (45.5%) were either divorced/separated or widowed. The latest CD4+ cell count at the time of interview was less than 350 c/mm³ for 224 (56%) participants, and 252 (56.0%) had HIV RNA less than 1000 c/ml.

Adherence rating
One hundred and seventy-nine participants (55.5%) had optimal adherence to ART. After adjusting for age, gender, education, marital status, CD4 cell count, duration on treatment, plasma HIV RNA levels and CTC sites, patients who knew their ART line of treatment and were aware that future treatment options were limited were more likely to have optimal adherence to ART than those who had no knowledge of their ART line of treatment and/or were unaware that future treatment options were limited (prevalence ratio [PR], 1.1; 95% CI, 1.0–1.3) (Table 2).

Several other factors were associated with ART adherence with the estimates about the same as that of knowledge on ART. For example, women were more likely (APR, 1.1; (1.0–1.3) than men to have optimal adherence to ART. Compared to patients who have been on treatment for less than 36 months, those who have been on treatment between 36 and 60 months were more likely to have optimal adherence [APR, 1.2; (1.0–1.3)]. CTC site was also positively associated with adherence to ART, and patients from Mawenzi Regional Hospital were more likely to have optimal adherence than those from the KCMC Consultant Hospital (APR, 1.2; (1.0–1.4). Plasma viral load was inversely associated with optimal adherence, as those patients with plasma HIV RNA levels ≥ 1000 c/ml were less likely to have optimal adherence compared to those whose HIV-RNA < 1000 c/ml [APR, 0.8; (0.7–0.9)].

Discussion
The importance of adherence to ART cannot be overemphasized. The reduction of morbidity and mortality related to HIV/AIDS and associated opportunistic infection among HIV-infected patients is clear among patients taking their medications as prescribed [16, 17]. Interventions to improve adherence to ART are a priority, and numerous interventions have been explored [18, 19]. In this study we demonstrated that knowledge on ART line of treatment as well as awareness of limited availability of future treatment options is an indicator of adherence. Patients who were aware of their ART line of treatment and who were also informed of limited future treatment options were 10–20% more likely to adhere to their medications than those who were not aware of either. Approximately three-quarters of the study participants were not aware of their ART line of treatment and/or did not know if future ART treatment options are limited, reflecting a general lack of knowledge and perspective on the use of ART regimens.

The main strengths of this study are that, to our knowledge, it is the first study that assesses association between patient knowledge on ART line of treatment, future treatment options and adherence to ART. The association between patient’s awareness of ART line of treatment and adherence has never been explored previously and is a unique feature of this study; however, some studies have shown associations between other components of ART knowledge and adherence. About 80% of HIV-infected adults in South Africa had poor knowledge of HIV and ART, and poor medication adherence was partly attributed to the poor knowledge [20]. The high proportion of patients with poor knowledge of ART in this South African study is similar to the observations in our study. The lack of knowledge in this setting could be factors at the patient and health care provider level. At the patient level, high level of illiteracy (83% had equal to or less than primary school education). Failure to attend ART education sessions also explains low level of knowledge. At the provider level, low doctor to patient ratio leads to reduced amount of time that physicians spend with the patients [21] thereby
limiting the amount of health education patient receives. In addition, absence of consistent health education or the presence of incompetent health educators who are not fully aware of ART regimens and their availability may explain the lack of this knowledge. Treatment preparation is an important component in the management of HIV patients, however, it may not be conducted across all sites as required and if conducted, it may not be done serially, which further may explain low levels of patient knowledge. Similar cross sectional analyses from

### Table 1 Demographic and Clinical Characteristics of HIV-Infected Patients Receiving Care at Five Care and Treatment Centers in Kilimanjaro Region, Moshi, Tanzania 2004–2015

| Characteristics                        | All Patients n = 402 | Optimal Adherence n = 223 | Sub-optimal Adherence n = 179 |
|----------------------------------------|----------------------|---------------------------|-------------------------------|
| Age                                    |                      |                           |                               |
| < 30                                   | 19 (4.7)             | 14 (6.3)                  | 5 (2.8)                       |
| 30–55                                  | 301 (74.9)           | 169 (75.8)                | 132 (73.7)                    |
| > 55                                   | 82 (20.4)            | 40 (17.9)                 | 42 (23.5)                     |
| Gender                                 |                      |                           |                               |
| Male                                   | 131 (32.9)           | 87 (39.0)                 | 44 (24.6)                     |
| Female                                 | 271 (67.1)           | 136 (61.0)                | 134 (75.4)                    |
| Education                              |                      |                           |                               |
| ≤ primary school education             | 332 (82.6)           | 188 (84.3)                | 144 (80.4)                    |
| > primary school education             | 70 (17.4)            | 35 (15.7)                 | 35 (19.6)                     |
| Marital status                         |                      |                           |                               |
| Not married                            | 57 (14.1)            | 33 (14.8)                 | 24 (13.4)                     |
| Married                                | 162 (40.3)           | 92 (41.3)                 | 80 (43.9)                     |
| Divorced/Separated/Widowed             | 183 (45.5)           | 98 (43.9)                 | 75 (47.5)                     |
| CD4 at the time of interview           |                      |                           |                               |
| < 350 cells/mm³                        | 224 (55.7)           | 129 (57.9)                | 95 (53.1)                     |
| ≥ 350 cells/mm³                        | 178 (44.3)           | 94 (42.1)                 | 84 (46.9)                     |
| Duration on treatment                  |                      |                           |                               |
| < 36 months                            | 130 (32.3)           | 67 (30.0)                 | 63 (35.2)                     |
| 36–60 months                           | 73 (18.2)            | 49 (22.0)                 | 24 (14.4)                     |
| > 60 months                            | 199 (49.5)           | 107 (48.0)                | 92 (51.4)                     |
| Knowledge of ART                       |                      |                           |                               |
| No                                     | 301 (74.9)           | 158 (70.8)                | 143 (79.9)                    |
| Yes                                    | 101 (25.1)           | 65 (29.2)                 | 36 (20.1)                     |
| Knows is on first-line ART             |                      |                           |                               |
| No                                     | 321 (79.9)           | 173 (77.6)                | 148 (82.7)                    |
| Yes                                    | 81 (20.1)            | 50 (22.4)                 | 31 (17.3)                     |
| Knows other options are limited        |                      |                           |                               |
| No                                     | 317 (78.9)           | 168 (75.3)                | 149 (83.2)                    |
| Yes                                    | 85 (21.1)            | 55 (24.7)                 | 30 (16.8)                     |
| Plasma HIV RNA level                   |                      |                           |                               |
| < 1000 c/ml                            | 252 (56.0)           | 88 (44.7)                 | 164 (64.8)                    |
| ≥ 1000 c/ml                            | 198 (44.0)           | 109 (55.3)                | 89 (35.2)                     |
| Sites                                  |                      |                           |                               |
| KCMC                                   | 75 (16.7)            | 52 (26.4)                 | 23 (9.1)                      |
| Mawenzi                                | 223 (55.9)           | 69 (35.0)                 | 154 (60.9)                    |
| Others                                 | 152 (33.8)           | 76 (38.6)                 | 76 (30.0)                     |

Abbreviations: KCMC Kilimanjaro Christian Medical Center, N/A Not applicable, HIV RNA Human Immunodeficiency Virus Ribonucleic Acid
African setting reported low level of knowledge about other component of ART some of which were associated with poor adherent. For example, a study done in Togo showed that only 55% of the HIV-infected patients were aware of the names of their prescribed ART medication(s) [22]. Over 90% of HIV-infected women in Ghana had inadequate knowledge on ART, and these women were much more likely to default from PMTC care [23].

A study of the association of knowledge on the treatment plan, regimen and adherence was conducted in Ethiopia. About 33% had knowledge on the treatment plan and regimen, and those who had knowledge were more likely to be adherent than those who did not [24], suggesting knowledge on different components of ART is crucial in improving patient adherence. We have also been able to show gender variations in ART adherence in that women tended to be more likely than men to adhere to ART medications. A number of studies substantiated this finding [25, 26]. In addition, recognizing adherence wanes over time [12, 13], we used 24-month self-reported patient information to assess cumulative adherence.

Virological outcome was also correlated with adherence among study participants. Patients whose viral loads were more than 1000c/ml were less likely to be adherent than

Table 2  Crude and Adjusted Risk Factors of Optimal Adherence to First-Line ART among HIV-Infected Adults Receiving Care at Five Care and Treatment Centers in Kilimanjaro Region, Moshi, Tanzania 2004–2015

| Characteristics | Bivariable Analysis Prevalence | Multivariable Analysis Prevalence |
|-----------------|-------------------------------|----------------------------------|
|                 | Ratio 95 % CI                  | Ratio 95 % CI                    |
| Age             |                               |                                 |
| < 30            | 1                             | 1                                |
| 30–55           | 0.8 (0.6–1.0)                 | 0.8 (0.6–1.1)                    |
| > 55            | 0.7 (0.5–0.9)                 | 0.8 (0.6–1.0)                    |
| Gender          |                               |                                 |
| Male            | 1                             | 1                                |
| Female          | 1.3 (1.1–1.6)                 | 1.1 (1.0–1.3)                    |
| Education       |                               |                                 |
| ≤ primary school education | 1 | 1 |
| > primary school education | 0.9 (0.7–1.1) | 0.9 (0.8–1.1) |
| Marital status  |                               |                                 |
| Not married     | 1                             | 1                                |
| Married         | 1.0 (0.8–1.2)                 | 1.0 (0.8–1.3)                    |
| Divorced/Separated/Widowed | 0.9 (0.7–1.2) | 1.0 (0.8–1.3) |
| CD4 at the time of interview |               |                                 |
| < 350 cells/mm³ | 0.9 (0.8–1.1)                 | 1.0 (0.9–1.1)                    |
| ≥ 350 cells/mm³ | 1                             | 1                                |
| Duration on treatment |               |                                 |
| < 36 months    | 1                             | 1                                |
| 36–60 months   | 1.3 (1.0–1.6)                 | 1.2 (1.0–1.3)                    |
| > 60 months    | 1.0 (0.8–1.3)                 | 1.0 (0.9–1.2)                    |
| Knowledge of ART |                             |                                 |
| No             | 1                             | 1                                |
| Yes            | 1.2 (1.0–1.5)                 | 1.1 (1.0–1.3)                    |
| Plasma HIV RNA level |               |                                 |
| < 1000 c/ml    | 0.6 (0.5–0.7)                 | 0.8 (0.7–0.9)                    |
| ≥ 1000 c/ml    | 1                             | 1                                |
| Sites          |                               |                                 |
| KCMC           | 1                             | 1                                |
| Mawenzi        | 1.3 (1.0–1.8)                 | 1.2 (1.0–1.4)                    |
| Others         | 1.1 (0.8–1.6)                 | 1.1 (0.9–1.4)                    |

Abbreviations: KCMC Kilimanjaro Christian Medical Center, N/A Not applicable, HIV RNA Human Immunodeficiency Virus Ribonucleic Acid
those whose viral loads were less than 1000c/ml, confirming the role of adherence in viral load suppression as evidenced in multiple studies [1–3].

Our study does have a number of limitations. Although we assessed cumulative adherence, it was from self-reported patient information collected by health care providers. Self-reported adherence is subject to over-estimation of adherence percentages. Nevertheless, in this study we were able to correlate optimal adherence with viral load results. When the viral loads were related to patient adherence, those with higher viral loads (≥1000c/ml) were less likely to be adherent than those with lower viral load (<1000 c/ml). Such a finding suggests that our adherence percentages may have not been overestimated. In addition, self-reported adherence measurement has been extensively used and is associated with clinical, immunological and virological outcomes for patients [11, 27]. In addition, with a cross-sectional study design to assess association between knowledge of ART and adherence, the study design cannot establish a temporal association or causality. Furthermore, because we limited patients who have been on treatment for at least 2 years from the primary data, selection bias is a potential concern. The study might not have captured representative patients to address the research question. However, knowledge of different components of ART has shown to be important indicator of adherence in other studies.

Conclusion
The study reports patient knowledge of ART line of treatment and future treatment options as an indicator of adherence to ART. Although majority of the patients did not have the knowledge, those who had the knowledge were demonstrated to be more adherent. It is critical for the health care providers in resource-limited settings to clearly educate patients about ART line of treatment and limited availability of future treatment options, and such information may influence individual behavior and improve patient adherence with ART.

Acknowledgments
We thank the management of the 5 CTCs for invaluable assistance in conducting the study. We also thank study participants and other staff members for their assistance with this study. Moreover, we thank Godfrey Mushii, Gaudensia H. Lyimo and Rita P. Minja for conducting patient interviews and data collection.

Funding
This research was supported by the Duke Center For AIDS Research (CFAR), a National Institutes of Health-funded program (P30 AI064518-06).

Availability of data and materials
All data supporting our findings is contained in the manuscript. There are no restrictions to data sources but details of the full data may be accessed through the Principal Investigator (PI), Dr Habib Ramadhan Omari (Kilimanjaro Christian Medical Center, Postal Address: 3010; Moshi, Tanzania. E-mail: habibrama@gmail.com).

Authors’ contributions
HRO carried out all data analysis and prepared the manuscript as the principle investigator. VPM was the focal person for KCMC site and contributed to the manuscript. CM helped designing questionnaires and assisted on writing the manuscript. MO performed viral load tests and contributed to the manuscript write up. EL was Kibocho site supervisor and assisted with questionnaire design. JBM was Kilena supervisor and assisted on questionnaire design. JAB was senior HIV specialist who advised on study design and assist on manuscript write up. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Institutional Review Board approval was obtained from the Kilimanjaro Christian Medical University College (KCMU-Co) clearance number: 277 and Duke University Health System (DUHS) clearance number: CR003_Pro00032975. Informed consent (written and verbal) was obtained from the each participant prior to interviews and data collection. Informed consent included information related to purpose of the study, potential risks and benefits of participating, procedures of maintaining confidentiality, right to or not to participate in this study, as well as right to withdraw from interview at any point; were provided to the research subject.

Author details
1Kilimanjaro Christian Medical Centre (KCMC), P.O Box 3010 Moshi, Kilimanjaro, Tanzania. 2Kilimanjaro Christian Medical University College, Moshi, Tanzania. 3Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC, USA. 4Duke Global health Institute, Durham, NC, USA. 5Kilema Designated District Hospital, Moshi, Tanzania. 6Kibocho Designated District Hospital, Moshi, Tanzania.

Received: 1 December 2015 Accepted: 17 June 2016
Published online: 15 July 2016

References
1. Saffrin SA, Mayer KH, Ou SS, McCauley M, Grinsztejn B, Hosseinipour MC, et al. Adherence to early antiretroviral therapy: results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. J Acquir Immune Defic Syndr. 2015;69(2):234–40.
2. Koss CA, Natuweeba P, Mweisiwa J, Cohan D, Nazarubara B, Bacchetti P, et al. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS (London, England). 2015;29(7):825–30.
3. Bangsberg DR, Hecht FM, Chaifebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England). 2000;14(8):357–66.
4. Ramadhan HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, et al. Association of first-line and second-line antiretroviral therapy adherence. Open forum Infectious Dis. 2014;1(2):ofu079.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
6. Patelson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
7. Bangsberg DR, Knetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Current HIV/AIDS Rep. 2007;4(2):65–72.
8. Patieni JI, Das-Douglas M, Massari Y, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3(7):e2783.
9. Zachariah R, Van Engelgem I, Massauci M, Kocholla L, Manzi M, Suleh A, et al. Payment for antiretroviral drugs is associated with a higher rate of
patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya. Trans R Soc Trop Med Hyg. 2008;102(3):288–93.
10. Senkomago V, Guwatudde D, Breda M, Khoshnood K. Barriers to antiretroviral adherence in HIV-positive patients receiving free medication in Kayunga, Uganda. AIDS care. 2011;23(10):1246–53.
11. Ramadhani HO, Thelman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.
12. Mbone M, Seeley J, Siembaja F, Birungi J, Jaffar S. Adherence to antiretroviral therapy in Jinja, Uganda: a Six-year follow-Up study. PLoS One. 2013;8(10):e78243.
13. Wilson IB, Bangsberg DR, Shen J, Simoni JM, Reynolds NR, Goggin K, et al. Heterogeneity among studies in rates of decline of ART adherence over time: results from the MACH14 study. J Acquir Immune Defic Syndr. 2013;64:448–54.
14. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.
15. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3):e17518.
16. Slaymaker E, Todd J, Marston M, Calvert C, Michael D, Nakyingi-Miloro J, et al. How have ART treatment programmes changed the patterns of excess mortality in people living with HIV? Estimates from four countries in East and Southern Africa. Glob Health Action. 2014;7:22789.
17. Kanjala C, Michael D, Todd J, Slaymaker E, Calvert C, Isingo R, et al. Using HIV-attributable mortality to assess the impact of antiretroviral therapy on adult mortality in rural Tanzania. Glob Health Action. 2014;7:21865.
18. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in AIDS care panel. Ann Intern Med. 2012;156(11):817–29.
19. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;11(12):942–51.
20. Terblanche LM, Stellenberg EL. Patient knowledge of HIV and its treatment in South Africa. African J Prim Health care Family Med. 2014;6(1):E1–7.
21. http://www.intrahealth.org/page/tanzania Accessed 20 Apr 2016.
22. Potchoo Y, Tchamdja K, Chimbindi N, Peoples A, Haberer J, Newell ML. Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association “Espoir Vie Togo” in Togo, West Africa. BMC Clin Pharmacol. 2010;10:11.
23. Boateng D, Kvapong GD, Agyei-Baffour P, Knowledge, perception about antiretroviral therapy (ART) and prevention of mother-to-child-transmission (PMTCT) and adherence to ART among HIV positive women in the Ashanti Region, Ghana: a cross-sectional study. BMC Womens Health. 2013;13:2.
24. Demesse R, Melkonnen A, Amogne W, Shbeshi W. Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS at Tikur Anbessa Specialized Hospital, Ethiopia. Int J Basic Clin Pharmacol. 2014;3(2):320–30.
25. Wasti SP, Simkhada P, Randall J, Freeman JV, van Teijlingen E. Factors influencing adherence to antiretroviral treatment in Nepal: a mixed-methods study. PLoS One. 2012;7(5):e35547.
26. Sasaki Y, Kakimoto K, Dube C, Skaizwe I, Moyo C, Syakantu G, et al. Adherence to antiretroviral therapy (ART) during the early months of treatment in rural Zambia: influence of demographic characteristics and social surroundings of patients. Ann Clin Microbiol Antimicrob. 2012;11:34.
27. Gare J, Kelly-Hanku A, Ryan CE, David M, Kaima P, Imara U, et al. Factors influencing antiretroviral adherence and virological outcomes in people living with HIV in the highlands of Papua New Guinea. PLoS One. 2015;10(8):e0134918.